mosquito
certain
bite
fli
tick
anim
transfus
contamin
blood
deadliest
horrifi
diseas
world
ever
seen
initi
virus
smallpox
epidem
disast
describ
ancient
sanskrit
medic
text
date
bc
europ
smallpox
like
appear
ad
rabi
histori
date
back
bc
describ
babylonian
went
mad
die
bitten
dog
bubon
plagu
arriv
europ
genoes
trade
ship
dock
sicilian
port
ship
carri
good
brought
bubon
plagu
caus
black
death
kill
million
peopl
europealmost
onethird
contin
popul
believ
plagu
viru
similar
ebola
viru
recent
deadli
viru
name
ebola
river
democrat
republ
congo
classifi
one
danger
pathogen
planet
still
million
case
dengu
fever
year
marburg
ebola
hemorrhag
fever
fatal
rate
influenza
swept
mediterranean
western
europ
diseas
caus
high
mortal
poultri
becam
known
fowl
plagu
fowl
plagu
call
highli
pathogen
avian
influenza
famou
disast
gener
virus
occur
spanish
flu
influenza
infect
world
popul
kill
million
million
peopl
pandem
happen
consid
one
worst
human
histori
probabl
viru
claim
credit
worldwid
pandem
scare
constantli
mutat
thousand
strain
influenza
asian
flu
caus
second
pandem
centuri
began
china
kill
one
million
peopl
worldwid
hong
kong
flu
caus
last
flu
pandem
swine
flu
outbreak
hit
origin
mexico
citi
quickli
spread
nation
first
case
hiv
infect
human
identifi
first
case
hiv
unit
state
date
back
hiv
caus
hiv
infect
aid
discov
hiv
infect
distinct
aid
fullblown
syndrom
along
consequ
damag
immun
system
often
fatal
million
peopl
infect
hiv
sinc
start
epidem
aidsrel
ill
sixth
lead
caus
death
virus
small
particl
much
smaller
fungi
bacteria
strang
substanc
someth
straddl
live
nonliv
particl
virus
basic
pack
genet
materialeith
dna
rnacarri
shell
made
protein
virus
addit
layer
call
envelop
virus
vari
size
complex
common
featur
speci
virus
nucleic
acid
protein
coat
lipid
membran
envelop
virus
divid
two
major
categori
envelop
nonenvelop
viru
particl
consist
outer
protein
shell
call
capsid
inner
core
nucleic
acid
either
ribonucl
deoxyribonucl
call
virion
virus
classifi
dna
virus
rna
virus
depend
whether
use
dna
rna
replic
classif
base
natur
genet
materi
packag
viru
singlestrand
doublestrand
rna
virus
analogu
dna
virus
other
virus
ca
nt
even
consid
cell
ca
nt
metabol
nutrient
produc
excret
wast
move
around
even
reproduc
unless
insid
anoth
organ
cell
come
contact
host
cell
fuse
host
cell
insert
genet
materi
cell
take
machineri
replic
consequ
controversi
regard
whether
virus
realli
consid
live
organ
viru
enter
cell
start
activ
first
step
must
attach
receptor
cell
surfac
viru
specif
receptor
vital
compon
cell
surfac
select
virus
determin
cell
prefer
instanc
rhinovirus
prefer
airway
cell
hiv
infect
mainli
lymphocyt
macrophag
cluster
surfac
immun
cell
epsteinbarr
viru
rabi
viru
infect
b
lymphocyt
carri
complement
receptor
type
believ
influenza
virus
infect
cell
multistep
process
main
target
influenza
viru
columnar
epitheli
cell
trachea
bronchi
bronchiol
first
step
virus
intern
via
receptormedi
endocytosi
traffick
along
endocyt
pathway
endosom
ha
protein
hemagglutinin
catalyz
fusion
viral
endosom
membran
take
place
releas
viral
ribonucleoprotein
import
nucleu
viral
gene
express
replic
viru
enter
bodi
trigger
bodi
immun
defens
lymphocyt
monocyt
destroy
viru
cell
infect
bodi
surviv
viru
attack
becom
abl
respond
subsequ
infect
viru
immun
also
produc
vaccin
vaccin
possibl
prevent
infect
virus
hepat
b
varicellazost
influenza
b
yellow
fever
polioviru
virus
infect
caus
hiv
hepat
c
herp
simplex
cytomegaloviru
hemorrhag
fever
virus
except
yellow
fever
viru
one
classif
virus
base
pathogen
properti
mode
transmiss
respiratori
virusesinfluenza
rhinoviru
adenovirusar
usual
acquir
inhal
droplet
replic
respiratori
tract
poliovirus
rotavirus
reovirus
adenovirus
enter
virus
virus
replic
gut
caus
gastric
infect
seriou
complic
includ
mening
enceph
poliomyel
myocard
arbovirus
infect
insect
ingest
vertebr
blood
replic
tissu
insect
transmit
vertebr
host
virus
includ
flavivirus
bunyavirus
rhabdovirus
sexual
transmit
virus
includ
hiv
herp
simplex
papilloma
virus
hepat
virus
caus
diseas
liver
differ
virus
isol
studi
date
histor
classif
diseas
relat
group
differ
hierarch
level
order
famili
subfamili
genu
speci
basi
properti
human
viral
infect
associ
loss
work
hour
includ
rhinovirus
influenza
viru
caus
influenza
calicivirus
norwalk
virus
astra
diarrheacaus
virus
virus
also
classifi
basi
morpholog
chemic
composit
mode
replic
reflect
small
part
spectrum
multitud
differ
virus
viral
diseas
treatabl
antibiot
cure
bacteri
diseas
infect
drug
combat
viral
infect
call
antivir
drug
effect
antivir
drug
mani
viral
infect
howev
sever
drug
influenza
coupl
drug
herpesvirus
new
antivir
drug
treatment
hiv
hepat
c
infect
arsen
antivir
complex
march
consist
approxim
drug
approv
fda
approxim
half
direct
hiv
antivir
drug
creation
strategi
focus
two
differ
approach
target
virus
target
host
cell
factor
approach
wide
review
first
event
viral
infect
host
cell
bind
viru
cell
surfac
involv
numer
interact
virion
surfac
receptor
virus
specif
attach
site
wide
distribut
host
cell
membran
recogn
molecul
surfac
viru
particl
mani
virus
use
attach
site
heparan
sulphat
proteoglycan
found
cell
surfac
block
initi
aspecif
bind
viru
cell
polyanion
compound
polysulf
ie
dextran
sulfat
polysulfon
polycarboxyl
polyoxometal
neg
charg
albumin
suggest
seri
potent
select
inhibitor
respiratori
virus
experiment
condit
pyrrolopyridin
compound
block
interact
viru
receptor
therebi
significantli
reduc
prolifer
propos
antihiv
therapeut
fig
anoth
exampl
compound
block
initi
bind
viru
cell
hydrolyt
enzym
neuraminidas
inhibitor
influenza
neuraminidas
surfac
glycoprotein
cleav
cellreceptor
sialic
acid
residu
therebi
allow
releas
viru
infect
new
cell
neuraminidas
inhibitor
commonli
use
prevent
treatment
influenza
sever
neuraminidas
inhibitor
develop
includ
oseltamivir
tamiflu
zanamivir
first
use
clinic
antiflu
therapi
laninamivir
peramivir
also
approv
northeast
asia
china
japan
south
korea
recent
agent
proven
safe
effect
alon
combin
treatment
uncompl
influenza
fig
anoth
way
prevent
bind
viru
host
cell
vaccin
immun
use
antibodi
specif
immunoglobulin
infect
agent
attach
host
cell
second
step
viral
replic
cycl
penetr
envelop
virus
penetr
fusion
viral
membran
cell
membran
nake
virus
penetr
cell
phagocytosi
virion
releas
viral
genom
host
cytoplasm
reason
entri
inhibitor
becam
one
major
concept
develop
new
antivir
drug
play
big
role
antivir
therapi
fusion
inhibitor
design
block
conform
chang
requir
membran
fusion
enfuvirtid
first
clinic
approv
fusion
inhibitor
inhibit
broad
rang
envelop
viru
particularli
hiv
strain
enfuvirtid
actyrthrserleuilehisserleuileglugluserglnasnglnglnglulysasngluglngluleuleugluleuasplystrpalaserleutrpasntrpphenh
first
novel
class
peptid
fusion
inhibitor
consid
activ
disrupt
molecular
machineri
final
stage
fusion
target
cell
seri
modifi
peptid
includ
peptid
fusion
inhibitor
possess
potent
antihiv
activ
name
sifuvirtid
synthes
modifi
pegyl
glycosyl
process
plethora
small
molecul
fusion
inhibitor
synthes
difficulti
product
deliveri
none
approv
clinic
use
pleconaril
entri
inhibitor
nonenvelop
virus
prevent
viru
attach
host
cell
prime
exampl
human
rhinoviru
inhibitor
propos
capsidtarget
molecul
name
clinic
develop
entri
inhibitor
primarili
target
envelop
glycoprotein
cellular
receptor
chemokin
receptor
involv
number
biolog
process
enter
cell
via
one
chemokin
receptor
ccchemokin
receptor
antagonist
maraviroc
approv
drug
novel
class
antiretrovir
agent
prevent
entri
host
cell
block
coreceptor
fig
anoth
antivir
drug
target
uncoat
step
viral
infect
process
capsid
disintegr
retain
viru
encapsul
state
allow
viru
releas
genom
materi
host
cell
interrupt
viru
replic
cycl
proce
revers
transcriptas
step
believ
drug
work
block
ion
channel
viru
amantadin
rimantadin
repres
uncoat
inhibitor
specif
prevent
releas
influenza
viru
cell
date
compound
shown
act
uncoat
hiv
retrovirus
fig
proteas
essenti
enzym
regul
number
process
infect
fertil
allerg
reaction
inflamm
blood
clot
cell
growth
death
bone
remodel
becom
remark
target
promis
therapeut
agent
proteas
inhibitor
enzym
critic
divers
biolog
process
involv
life
cycl
virus
replic
process
proteas
inhibitor
becam
import
constitu
antiretrovir
drug
armada
particular
prevent
viral
replic
block
proteolyt
cleavag
protein
precursor
necessari
product
infecti
particl
note
virus
also
encod
proteas
protect
viral
protein
modul
host
cell
proteas
inhibitor
major
therapeut
breakthrough
treatment
hiv
infect
usher
era
highli
activ
antiretrovir
therapi
among
antihiv
drug
develop
past
two
decad
inhibitor
proteas
revers
transcriptas
found
promin
clinic
use
creation
seri
proteas
inhibitor
one
great
success
antivir
drug
design
earli
research
involv
quest
among
suitabl
peptid
final
conclud
decreas
peptidelik
featur
minim
size
molecul
current
approv
proteas
inhibitor
mainli
creat
principl
structureand
fragmentbas
drug
design
includ
nelfinavir
amprenavir
synthesi
darunavir
seri
darunavir
analogu
display
impress
enzymat
antivir
properti
repres
promis
lead
compound
optim
darunavir
uniqu
recent
extrem
potent
proteas
inhibitor
drug
use
treat
hiv
infect
darunavir
usual
use
combin
ritonavir
medicin
maintain
antiretrovir
activ
varieti
multidrugresist
hiv
strain
darunavir
caus
seriou
lifethreaten
side
effect
includ
liver
problem
sever
skin
reaction
rash
origin
synthesi
atazanavir
carri
reaction
boc
benzyl
hydrazin
epoxid
prepar
accord
known
procedur
anoth
effici
practic
synthesi
atazanavir
develop
employ
diastereoselect
reduct
ketomethylen
azadipeptid
key
final
step
assembl
two
key
intermedi
hydrazid
deriv
hydrazid
synthes
alreadi
known
benzaldehyd
special
case
prepar
kumada
coupl
grignard
reagent
condens
aldehyd
n
methoxycarbonyl
ltertleucinyl
hydrazin
carri
ethanol
result
mixtur
subject
next
reaction
without
purif
quantit
hydrogen
use
pd
oh
c
ethanol
proceed
high
yield
high
puriti
produc
desir
hydrazid
second
key
reagent
chloromethyl
keton
prepar
reaction
mix
anhydrid
turn
prepar
n
methoxycarbonyl
ltertleucin
isobutyl
chloroform
atazanavir
novel
potent
safe
gener
welltoler
inhibitor
hiv
proteas
first
date
proteas
inhibitor
design
appli
daili
atazanavir
expect
overcom
problem
earlier
agent
class
drug
unfavor
advers
event
like
hyperlipidemia
diarrhea
lipodystrophi
combin
nucleosid
revers
transcriptas
inhibitor
boost
ritonavir
establish
prefer
initi
regimen
publish
guidelin
first
public
describ
synthesi
ritonavir
final
compound
convert
correspond
free
acid
lioh
dioxanewat
mixtur
scheme
slightli
differ
approach
demonstr
patent
describ
new
method
prepar
key
diaminoalcohol
intermedi
synthesi
ritonavir
describ
reaction
lphenylalanin
benzyl
chlorid
use
k
co
koh
hot
water
produc
lphenylalanin
benzyl
ester
condens
first
acetonitril
presenc
nanh
react
benzylmagnesium
chlorid
methyl
tertbutyl
ether
yield
dibenzylamino
reduct
obtain
product
nabh
result
enhanc
enantioselect
toward
desir
enantiom
dibenzylamino
final
compound
debenzyl
hydrogen
ammonium
format
pdc
methanolwat
provid
target
chiral
diaminoalcohol
transform
ritonavir
scheme
differ
variat
approach
publish
ritonavir
potent
inhibitor
proteas
encod
clinic
appli
suppress
replic
aid
patient
ritonavir
cure
hiv
aid
may
slow
progress
diseas
reduc
amount
viru
bodi
good
oral
bioavail
may
increas
bioavail
proteas
inhibitor
includ
saquinavir
nelfinavir
indinavir
ritonavir
caus
clinic
signific
increas
serum
level
proteas
inhibitor
darunavir
fosamprenavir
lopinavir
saquinavir
often
use
combin
first
report
new
proteas
inhibitor
candid
lopinavir
seem
abbott
patent
core
lopinavir
ident
ritonavir
end
group
ritonavir
replac
phenoxyacetyl
group
group
ritonavir
replac
modifi
valin
amino
terminu
sixmemb
cyclic
urea
attach
synthet
strategi
employ
synthesi
multikilogram
quantiti
lopinavir
similar
implement
ritonavir
use
protect
version
core
diamino
alcohol
sequenti
acyl
acid
chlorid
yl
butano
acid
acet
acid
bulk
synthesi
protect
diamino
alcohol
propos
method
close
relat
method
ritonavir
purpos
lphenylalanin
sequenti
trialkyl
benzyl
chlorid
use
k
co
water
system
reflux
produc
tribenzyl
product
solut
gener
acetonitril
anion
thf
ad
benzyl
product
less
yield
cyanomethylketon
expos
grignard
reagentbenzyl
magnesium
chlorid
produc
enaminon
racem
observ
two
step
addit
obtain
enaminon
thfproh
solut
nabh
msoh
thf
produc
intermedi
aminoketon
reduct
keto
group
occur
condit
reduct
keto
group
could
proceed
addit
preform
solut
sodium
tri
trifluoroacetoxi
borohydrid
tetrahydrofuran
nabh
otfa
produc
mixtur
amino
alcohol
compos
desir
dibenzylamino
along
three
undesir
diastereom
crude
mixtur
debenzyl
pdc
hconh
product
purifi
precipit
iprohhcl
aq
produc
greater
puriti
high
yield
scheme
effici
synthesi
side
chain
moieti
coupl
core
diamino
alcohol
deriv
develop
follow
yl
butano
acid
prepar
start
lvalin
first
convert
nphenoxycarbonyllvalin
phenylchloroform
accur
ph
monitor
ph
necessari
lioh
found
superior
base
control
ph
essenti
valin
dimer
deriv
form
reaction
byproduct
outsid
ph
margin
licl
ad
provid
lower
freez
point
aqueou
solut
neutral
al
ad
prevent
gum
emuls
format
cours
reaction
wellknown
peptid
coupl
method
optim
transform
allow
discoveri
costeffect
method
implement
acyl
chlorid
easili
prepar
use
thionyl
chlorid
thf
room
temperatur
reaction
dibenzylamino
alcohol
n
twophas
solvent
system
presenc
water
solut
nahco
liber
free
amin
produc
desir
lopinavir
high
yield
puriti
scheme
lopinavir
novel
strong
proteas
inhibitor
develop
ritonavir
high
specif
proteas
indic
combin
antiretrovir
agent
treatment
infect
numer
clinic
trial
shown
lopinavirritonavir
kaletra
highli
effect
compon
highli
activ
antiretrovir
therapi
polymeras
enzym
essenti
requir
replic
virus
viral
dna
rna
polymeras
respons
copi
genet
materi
virus
transcript
replic
therefor
central
compon
life
cycl
virus
polymeras
inhibitor
block
enzymat
function
thu
prevent
viru
multipli
group
antivir
medic
consist
two
class
nucleosid
inhibitor
nonnucleosid
inhibitor
contrast
nucleosid
inhibitor
bind
activ
site
polymeras
nonnucleosid
inhibitor
bind
alloster
bind
site
within
polymeras
thu
block
action
along
nucleosid
nonnucleosid
polymeras
inhibitor
exist
class
nucleotid
nonnucleotid
polymeras
inhibitor
polymeras
inhibitor
classifi
also
dna
rna
polymeras
inhibitor
nucleosid
viral
dna
polymeras
specif
target
number
antivir
drug
current
use
inhibit
viral
replic
antivir
approv
drug
inhibit
dna
polymeras
nucleosid
analogu
repres
product
sourc
antivir
agent
agent
need
phosphoryl
activ
form
activ
form
inhibit
polymeras
compet
natur
substrat
incorpor
grow
dna
chain
way
termin
viral
dna
elong
dna
polymeras
inhibitor
acyclovir
fig
ribavirin
inhibit
guanosin
triphosph
format
prevent
cap
viral
mrna
block
deriv
resembl
viral
rnadepend
rna
polymeras
activ
recent
year
antivir
drug
discoveri
platform
util
highthroughput
screen
technolog
ht
enabl
discoveri
mani
initi
lead
seri
nonnucleosid
viral
rna
polymeras
inhibitor
viral
dna
polymeras
inhibitor
acyclovir
valacyclovir
valganciclovir
tenofovir
includ
list
top
drug
sale
synthesi
forerunn
polymeras
inhibitorsacyclovir
antiherp
drugwa
first
describ
disclos
detail
later
synthesi
start
benzonitril
heat
reflux
ethylen
glycol
hour
produc
ethylen
glycol
monobenzo
conveni
econom
synthesi
acyclovir
report
synthesi
start
easili
avail
mixtur
n
prepar
acyl
guanin
acet
anhydrideacet
acid
mixtur
obtain
commixtur
compound
condens
diacet
presenc
ptoluenesulfon
acid
without
solvent
dmso
produc
satisfactori
yield
desir
separ
crystallin
intermedi
without
necess
column
purif
deprotect
compound
aqueou
menh
minut
produc
acyclovir
overal
yield
effect
hydrolysi
acetyl
protect
group
possibl
also
use
ammonia
meoh
aqueou
naoh
room
temperatur
pyrrolidin
room
temperatur
via
reflux
glycol
whatev
etc
variat
method
report
review
scheme
scheme
synthesi
acyclovir
anoth
approach
synthesi
acyclovir
demonstr
start
avail
alkyl
benzoyloxi
ethoxymethyl
chlorid
dimethylformamid
presenc
triethylamin
produc
mixtur
desir
compound
deformyl
product
mixtur
reformyl
aceticform
anhydrid
produc
crude
reduct
cleavag
furazan
ring
obtain
product
zinc
dust
acet
acid
follow
heat
facilit
cycliz
produc
adenin
protect
benzoyl
group
cleav
aqueou
methylamin
heat
steam
bath
produc
group
fail
react
liquid
ammonia
reason
group
mention
compound
transform
hydroxyl
group
sodium
nitrit
acet
acid
yield
subsequ
amin
ammonia
satur
ethanol
autoclav
produc
desir
acyclovir
scheme
approach
differ
detail
describ
review
acyclovir
close
relat
natur
compon
dna
guanin
deoxyribosid
act
prevent
dna
replic
dna
viru
concentr
far
affect
cellular
dna
discoveri
acyclovir
nucleosid
analogu
year
ago
repres
mileston
acyclovir
drug
choic
prophylact
cur
treatment
herp
simplex
genit
herp
viru
varicellazost
shingl
viru
infect
remain
challeng
centuri
acyclovir
cure
herp
may
prevent
breakout
herp
sore
blister
virus
continu
live
bodi
even
outbreak
acyclovir
decreas
sever
length
outbreak
help
sore
heal
faster
keep
new
sore
form
decreas
pain
itch
acyclovir
formul
includ
inject
oral
topic
form
scheme
synthesi
acyclovir
valacyclovir
prodrug
deriv
esterifi
acyclovir
lvalin
quickli
absorb
well
toler
upon
administr
valacyclovir
rapidli
complet
convert
acyclovir
enzymat
hydrolysi
increas
oral
bioavail
threeto
fivefold
first
synthesi
valacyclovir
acyclovir
condens
ncarbobenzyloxylvalin
dmf
presenc
dicyclohexylcarbodiimid
provid
ncarbobenzyloxyprotect
valacyclovir
subject
palladium
catalyz
deprotect
pdal
dmf
furnish
valacyclovir
effici
scaleabl
process
accord
scheme
develop
later
approach
implement
anoth
protect
group
amino
acid
moieti
valacyclovir
prepar
reaction
n
boc
lvalin
acyclovir
use
hydrochlorid
edc
coupl
agent
hcl
deprotect
step
valacyclovir
use
treatment
herp
varicella
zoster
cytomegalovirus
discuss
clinic
pharmacolog
antivir
activ
clinic
efficaci
therapeut
issu
present
review
valganciclovir
synthet
approach
ganciclovir
report
valganciclovir
synthes
method
present
scheme
close
relat
present
ganciclovir
purpos
epichlorohydrin
react
benzyl
alcohol
presenc
powder
koh
toluen
room
temperatur
produc
benzyloxymethyloxiran
gaseou
hcl
bubbl
stir
mixtur
obtain
oxiran
paraformaldehyd
dichloromethan
produc
propan
chloromethyl
ether
react
potassium
acet
aceton
produc
propan
solut
diacetylguanin
propan
ptsoh
dmf
heat
hour
produc
flash
chromatographi
purif
chloro
deriv
product
previou
step
larg
excess
potassium
scheme
synthesi
ganciclovir
acet
dmf
heat
reflux
hour
produc
stir
last
ammoniamethanol
ambient
temperatur
produc
deprotect
compound
nbenzyloxycarbonyllvalin
dicyclohexylcarbodiimid
complex
prepar
dichloromethan
ad
suspens
dmf
follow
workup
mixtur
hour
produc
valin
obtain
product
deprotect
hydrogen
palladium
hydroxid
reflux
ethanol
produc
desir
valganciclovir
one
approach
ganciclovir
react
trimethyl
orthoform
orthoform
produc
cyclic
orthoest
treat
formic
acid
dmfh
yield
ganciclovir
omonoform
condens
ganciclovir
omonoform
nbenzyloxycarbonyllvalin
produc
monovalin
upon
deformyl
hcl
dichloromethanemethanol
mixtur
solvent
gave
rise
compound
deprotect
hydrogen
pdc
catalyst
produc
desir
valganciclovir
scheme
anoth
strategi
ganciclovir
protect
tritylchlorid
deriv
dmf
presenc
triethylamin
dmap
produc
correspond
n
obi
trityl
protect
compound
condens
n
benzyloxycarbonyl
lvalin
n
tertbutoxycarbonyl
lvalin
yield
correspond
valin
ester
thereaft
tritylprotect
group
remov
use
hot
aqueou
hydrochlor
acet
acid
trifluoroacet
acid
produc
follow
benzyloxycarbonyl
remov
hydrogen
pdc
obtain
valganciclovir
scheme
mani
close
relat
approach
also
publish
valganciclovir
effect
treatment
aidsrel
cmv
retin
prophylaxi
cytomegaloviru
infect
diseas
highrisk
solid
organ
transplant
recipi
drug
gener
well
toler
similar
toler
profil
devoid
advers
event
relat
intraven
indwel
cathet
access
associ
use
intraven
ganciclovir
group
includ
antivir
agent
mainli
recogn
treatment
hiv
usual
combin
retrovir
drug
hiv
spread
contin
identif
hiv
caus
agent
aid
start
novel
era
medicin
chemistri
result
first
antiretrovir
agent
azidothymidin
zidovudin
azt
develop
target
natur
class
virus
revers
transcriptas
enzym
control
replic
genet
materi
hiv
enzym
essenti
hiv
present
eukaryot
cell
discoveri
establish
first
class
antiretrovir
agent
nucleosid
nucleotid
revers
transcriptas
inhibitor
nucleosid
nucleotid
revers
transcriptas
inhibitor
analogu
endogen
nucleosid
nucleotid
chemic
point
repres
cytidin
guanosin
thymidin
adenosin
deriv
inact
parent
form
requir
phosphoryl
step
host
cell
kinas
phosphotransferas
form
triphosph
deriv
capabl
viral
inhibit
triphosph
form
compet
correspond
endogen
deoxynucleosid
triphosph
incorpor
hiv
revers
transcriptas
incorpor
serv
chaintermin
viral
revers
transcript
thu
act
viral
replic
cycl
inhibit
critic
step
provir
dna
synthesi
prior
integr
host
cell
genom
two
approach
synthesi
tenofovir
report
employ
readili
avail
reagent
one
base
alkyl
adenin
dmf
presenc
csco
chiral
ptoluenesulfonyloxymethanephosphon
turn
prepar
seven
step
isobutyl
lactat
deprotect
side
chain
obtain
use
standard
deprotectioncleavag
procedur
trimethylsilyl
bromid
reflux
acetonitril
produc
tenofovir
scheme
second
approach
adenin
transform
r
adenin
reaction
r
follow
deprotect
sulfur
acid
produc
desir
compound
select
protect
benzoyl
group
achiev
select
silyl
chlorotrimethylsilan
pyridin
follow
reaction
benzoyl
chlorid
obtain
r
alkyl
diisopropyl
ptoluenesulfonyloxymethanephosphon
dmf
presenc
sodium
hydrid
produc
compound
debenzoyl
amino
group
achiev
use
ammonium
hydroxid
solut
produc
whose
side
chain
deprotect
use
trimethylsilyl
bromid
reflux
acetonitril
produc
tenofovir
method
improv
convert
manufactur
process
largescal
synthesi
tenofovir
disoproxil
fumar
tenofovir
compon
prefer
firstlin
combin
antiretrovir
therapi
efficaci
toler
prolong
halflif
allow
oncedaili
administr
avail
compon
sever
fixeddos
formul
make
tenofovir
attract
choic
treatmentexperienc
hivinfect
patient
use
combin
antihiv
drug
sinc
approv
tenofovir
becom
one
frequent
prescrib
agent
hiv
infect
nonnucleosid
reversetranscriptas
inhibitor
repres
one
signific
class
drug
treatment
aidshiv
infect
crucial
compon
current
antiretrovir
therapi
drug
competit
nucleosid
revers
transcriptas
inhibitor
incorpor
viral
dna
work
differ
site
enzym
prevent
enzym
action
initi
discoveri
phenylthio
thymin
hept
follow
synthesi
emivirin
compound
seri
sever
chemic
class
compound
nonnucleosid
revers
transcriptas
inhibitor
properti
discov
includ
deriv
lovirid
find
follow
discoveri
first
drug
seri
known
first
gener
nonnucleosid
reversetranscriptas
inhibitor
includ
efavirenz
first
nonnucleosid
revers
transcriptas
inhibitor
approv
delavirdin
rare
use
nowaday
nevirapin
commerci
antihiv
drug
fig
sustain
effort
area
base
molecular
model
studi
led
identif
mani
promis
hit
lead
candid
yield
secondgener
nonnucleosid
reversetranscriptas
inhibitor
etravirin
approv
rilpivirin
approv
fig
tivirapin
variou
compound
hallmark
nonnucleosid
reversetranscriptas
inhibitor
abil
interact
specif
site
pocket
reversetranscriptas
fig
capravirin
anoth
secondgener
nonnucleosid
reversetranscriptas
inhibitor
studi
show
specif
advantag
current
use
drug
consequ
clinic
trial
discontinu
phase
iib
trial
fig
human
immunodefici
viru
infect
typic
treat
drug
combin
consist
least
three
differ
antiretrovir
drug
nonnucleosid
reversetranscriptas
inhibitor
essenti
compon
antiretrovir
therapi
integras
inhibitor
promis
group
novel
antiretrovir
drug
suppress
integraseenzym
facilit
incorpor
hiv
provir
dna
host
cell
genom
catalyz
function
vital
viral
replic
via
inhibit
integr
viral
dna
host
dna
genom
inhibitor
enzym
repres
newest
class
antiretrovir
drug
armamentarium
treat
viral
infect
earli
integras
inhibitor
includ
polyhydroxyl
aromat
compound
peptid
nucleotid
dna
complex
none
abl
develop
effect
drug
first
major
breakthrough
discoveri
pyrrolodiketo
acid
integras
inhibitor
flow
indolediketo
acid
naphthyridin
dihydroxypyrimidin
carboxamid
final
led
discoveri
raltegravir
raltegravir
first
integras
inhibitor
approv
treatment
hiv
infect
raltegravir
includ
list
top
drug
sale
elvitegravir
approv
late
anoth
potent
inhibitor
viral
integras
raltegravir
elvitegravir
consid
firstgener
integras
inhibitor
highli
efficaci
firstlin
antiretrovir
therapi
dolutegravir
secondgener
integras
inhibitor
current
review
fda
market
approv
fig
gener
synthet
rout
start
transform
aceton
cyanohydrin
taken
xylen
heat
hour
cycliz
obtain
compound
benzoyl
benzoic
acid
chlorid
pyridin
produc
purifi
flash
column
chromatographi
nmethyl
dimethyl
sulfat
dioxan
use
lithium
hydrid
base
provid
compound
prepar
hydrogen
presenc
pdc
produc
ndeprotect
product
acyl
freshli
prepar
chlorid
presenc
triethylamin
dichloromethan
final
reflux
prepar
overnight
pfluorobenzylamin
methanol
produc
desir
raltegravir
scheme
develop
effici
manufactur
raltegravir
publish
raltegravir
use
along
medic
treat
hiv
infect
caus
seriou
lifethreaten
side
effect
allerg
reaction
skin
reaction
liver
problem
number
class
compound
potenti
antivir
drug
attract
research
attent
last
year
among
methyltransferas
inhibitor
methyltransferas
catalyz
transfer
methyl
group
sadenosylmethionin
viral
rna
essenti
life
cycl
mani
signific
human
pathogen
virus
helicas
inhibitor
helicas
catalyt
unwind
duplex
dna
rna
requir
displac
singlestrand
genom
replic
neuraminidas
inhibitor
neuraminidas
inhibitor
interfer
releas
viru
infect
host
cell
replic
transcript
complex
blocker
reagent
effici
block
assembl
viral
replic
transcript
complex
respons
product
viral
genom
ribonucleoprotein
complex
inhibitor
inhibitor
thought
act
molecul
stapl
stabil
interact
viral
nucleoprotein
monom
promot
format
nonfunct
aggreg
antivir
current
use
exclus
target
viral
factor
sever
approach
focu
cellular
factor
pathway
indirectli
interact
viru
replic
among
inhibitor
intracellular
signal
cascad
essenti
viru
replic
replic
transcript
complex
blocker
block
format
viral
replic
transcript
complex
respons
product
viral
genom
nucleic
acid
ribonucleoprotein
complex
inhibitor
trigger
aggreg
inhibit
nuclear
accumul
viral
encod
nucleoprotein
therebi
inhibit
replic
viru
